Compare Bristol-Myers Squibb Co (BMY) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Prospect Capital Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Bristol-Myers Squibb Co is far larger — about 114× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (21.93%). Which is the better fit depends on your goals.
| BMY | PSEC | |
|---|---|---|
Market Cap | $129.94B | $1.14B |
Sector | Health | Financials |
52-Week High | $65.89 | $3.05 |
52-Week Low | $42.60 | $2.11 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | 21.93% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
